Rivoglitazone
| CAS No. | 185428-18-6 | Cat. No. | BCP06166 |
| Name | Rivoglitazone | ||
| Synonyms | CI-1037; CI 1037; CI1037; CS-011; CS011; CS011; DE-101; R-119702; | ||
| Formula | C20H19N3O4S | M. Wt | 397.45 |
| Description | Rivoglitazone is a peroxisome proliferator-activated receptor γ agonist (PARPγ agonist) potentially for the treatment of type 2 diabetes. Rivoglitazone has been shown, through small clinical studies, to decrease hemoglobin A(1c) (A1C) by 0.11-1.1% when compared with placebo and may provide greater A1C reduction than pioglitazone. Rivoglitazone reduces hyperglycemia, hyperinsulinemia, and hypertriglyceridemia by acting as an agonist of PPAR-γ. Rivoglitazone is the most potent PPAR-γ agonist. | ||
| Pathways | Cell Cycle/DNA Damage Epigenetics | ||
| Targets | PARP | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.